Notably, even though eIF4E levels are not homogeneous among ovarian cancer cell lines and tissues, ribavirin treatment reduced the growth and survival of ovarian cancer cell lines and increased the efficacy of cisplatin treatment both in vitro and in vivo[74], an observation that raises the possibility of combining it with other drugs for ovarian cancer therapy. This evidence concerns the gene EIF4E and ovarian carcinoma.